The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) is a huge mover today! About 1.82M shares traded hands. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 40.84% since March 15, 2016 and is downtrending. It has underperformed by 46.32% the S&P500.
The move comes after 6 months positive chart setup for the $4.29 billion company. It was reported on Oct, 18 by Barchart.com. We have $24.10 PT which if reached, will make NASDAQ:ENDP worth $900.90 million more.
Analysts await Endo International plc – Ordinary Shares (NASDAQ:ENDP) to report earnings on November, 3. They expect $0.84 EPS, down 17.65% or $0.18 from last year’s $1.02 per share. ENDP’s profit will be $180.90 million for 5.93 P/E if the $0.84 EPS becomes a reality. After $0.86 actual EPS reported by Endo International plc – Ordinary Shares for the previous quarter, Wall Street now forecasts -2.33% negative EPS growth.
Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage
Out of 16 analysts covering Endo International plc (NASDAQ:ENDP), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. Endo International plc has been the topic of 35 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by Leerink Swann given on Friday, May 6. The firm earned “Outperform” rating on Tuesday, August 11 by Leerink Swann. Mizuho initiated the shares of ENDP in a report on Friday, October 9 with “Buy” rating. The firm has “Underperform” rating given on Friday, May 6 by Mizuho. The firm earned “Overweight” rating on Monday, March 21 by JP Morgan. The company was downgraded on Friday, May 6 by Piper Jaffray. The rating was maintained by Barclays Capital with “Equal Weight” on Friday, May 6. BMO Capital Markets initiated the shares of ENDP in a report on Wednesday, June 29 with “Market Perform” rating. The firm earned “Outperform” rating on Thursday, September 29 by Northland Capital. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) has “Buy” rating given on Friday, May 6 by Stifel Nicolaus.
According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 0.95 in Q2 2016. Its up 0.03, from 0.92 in 2016Q1. The ratio improved, as 76 funds sold all Endo International plc – Ordinary Shares shares owned while 90 reduced positions. 42 funds bought stakes while 115 increased positions. They now own 192.40 million shares or 1.49% more from 189.57 million shares in 2016Q1.
Jensen holds 27,840 shares or 0.01% of its portfolio. Royal Bancorp Of Canada accumulated 32,425 shares or 0% of the stock. First Tru Advsr L P holds 0.03% or 517,586 shares in its portfolio. Icon Advisers Inc Com has 14,000 shares for 0.01% of their US portfolio. Henderson Gp Public Ltd Liability last reported 0% of its portfolio in the stock. Connor Clark And Lunn Inv Management Limited owns 661,964 shares or 0.08% of their US portfolio. Moreover, Croft has 0.37% invested in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 106,502 shares. Signaturefd Limited Liability Company has 1,068 shares for 0% of their US portfolio. Monroe Hall Asset Management Limited Liability last reported 2.42% of its portfolio in the stock. Globeflex Cap Lp holds 0.1% or 22,390 shares in its portfolio. Teacher Retirement System Of Texas last reported 0.05% of its portfolio in the stock. Gargoyle Invest Advisor Limited Co, a New Jersey-based fund reported 20,462 shares. Da Davidson owns 2,000 shares or 0% of their US portfolio. Shelton Cap holds 0.02% or 14,969 shares in its portfolio. Citigroup reported 135,644 shares or 0% of all its holdings.
More news for Endo International plc – Ordinary Shares (NASDAQ:ENDP) were recently published by: Valuewalk.com, which released: “Endo International plc â€“ Ordinary Shares (ENDP) Collapses Taking Hedge Fund …” on May 06, 2016. Valuewalk.com‘s article titled: “Endo International plc â€“ Ordinary Shares (ENDP) Shares Soar” and published on August 09, 2016 is yet another important article.
ENDP Company Profile
Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Companyâ€™s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.